Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Gene Therapy
32 Articles Available
0
2
Can't find what you're looking for? Try our
advanced search
.
Expansion
Cognate BioServices and its Gene Therapy Division Cobra Biologics Announce Major Expansion of Manufacturing Facilities in US and Europe
PR-M11-20-034
AAV Platform Technologies
Increasing Predictability with AAV Platform Technologies
PAP-Q4-20-CL-027
Gene Therapy
Anticipating the Next Decade of Gene Therapy
PAO-11-20-CL-02
CRISPR RNPs
CRISPR RNPs and the Future of Cell and Gene Therapy
PAP-Q3-20-CL-002
Cell & Gene Logistics
Standardizing Best Practices for Transporting Cell and Gene Therapies
PAP-Q3-20-CL-013
CRISPR-Cas9
How Close Is CRISPR to Eradicating Disease and Correcting Genetic Defects?
PAP-Q1-20-NI-003
Gene Therapy
Slow Progress and a Shaky Start—What’s Next for Gene Therapy?
PAP-Q4-19-NI-001
Gene Therapy
Introduction: The Promise & Challenge of Gene Therapy
PAP-Q4-19-NI-008
Gene Therapy
Gene Therapy R&D Accelerates
PAP-Q4-19-NI-002
Gene Therapy
Overcoming the Manufacturing Roadblock
PAP-Q4-19-NI-003
Gene Therapy
Promise Amid Challenges: Logistics of the Cell and Gene Therapy Supply Chain
PAP-Q4-19-NI-004
CRISPR-Cas9
CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway
PAP-Q4-19-CL-011
Plasmids
The Pivotal Role of Plasmid DNA
PAP-Q4-19-CL-006
Drug Approval
BioMarin Going for 2020 Approval of its Hemophilia A Gene Therapy
PAO-M08-19-NI-026
Integration
Building Upon an Integrated Biologics Offering
PTV-M08-19-BIO-005
Gene Therapy
Expanding GMP Gene Therapy Manufacturing Capacity
PTV-M08-19-BIO-003
Gene Therapy
Accelerating Innovation for Gene Therapy
PTV-M08-19-BIO-002
Cell and Gene Therapy
Aldevron to Build 14-Acre Gene Therapy Manufacturing Campus
PR-M06-NI-002
Cell and Gene Therapy
Precision BioSciences Aims for Significant Funding Support based on its ARCUS Gene Editing Tech
PAO-M03-19-NI-013
Cell and Gene Therapy
Massachusetts is Looking for Ways to Help Patients Receive Expensive Gene Therapy
PAO-M01-19-NI-022
FDA
FDA Gives Novartis Gene Replacement Therapy Application Priority Review
PAO-M12-18-NI-003
Licensing Agreement
REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors
PR-M10-18-NI-093
Cell and Gene Therapy
Analytical Methodologies Utilized in Therapeutic Viral Vector Manufacturing
PAP-Q3-18-CL-001
Gene Therapy
Understanding the Unique Design and Engineering Needs for Gene Therapy Production
PAP-Q3-18-CL-008
«
0
2
»
